Post by Tony Crispino on Apr 29, 2017 14:01:00 GMT -8
With my flight delayed I am sitting in a San Francisco airport terminal heading home from the SWOG cancer research summit. There year was one of the best of 14 meetings I have attended as the patient advocate for prostate cancer. The reason is because there are several new trials in the pipeline and many new approaches to treating prostate cancer being looked at. Let me recap one of them:
1. Standard systemic therapy (SST) v. SST for 6 months followed by definitive cytoreductive therapy in hormone sensitive metastatic patients. This phase III trial proposal originated at MD Anderson has wings and has been approved by SWOG executive committee and will be sent to the NIH for final approval in June. This trial can be on the streets before the SWOG Fall meeting in October. The highlights of the trial come from the completed Phase II where there is reasonable hypothesis that it will extend the median 44 months overall survival in these men to 57 months with some cases of full remission achieved. The trial will enroll 1200 men that will be randomized into two arms:
Schema:
De Novo Dx |SST until progression | OS
Stage T4x |Start ADT2| 6 months |If hormone sensitive Randomize |Definitive treatment 50% |OS
Surgery 67%, Radiation 33%
Other trials are looking at immune pathways in various settings. SWOG is working with the other co-ops to determine the best options for 2018.
Update on S1216 - SST v. Lupron plus TAK-700 in HSPC. This trial is enrolling 1300 men, is just 40 shy of closing, and will likely close by end of July. Whether or not TAK-700 will improve outcomes is not determined for two more years. However this trial will be one of the most beneficial trials to close as the secondary end points are huge pieces of information for CTC's and genetic biomarkers. Already the trial has validated CTC's as a predictive tool in metastatic men. Stay tuned on this one.
{Updated}
One of the key biomarkers in this trial is found in the tissue banking. These samples are taken before treatment begins (More than 1100 blood and 700 blocks thus far). And there is plenty to examine during disease progression making this trial the largest on record to take de novo sampling to be compared later.
1. Standard systemic therapy (SST) v. SST for 6 months followed by definitive cytoreductive therapy in hormone sensitive metastatic patients. This phase III trial proposal originated at MD Anderson has wings and has been approved by SWOG executive committee and will be sent to the NIH for final approval in June. This trial can be on the streets before the SWOG Fall meeting in October. The highlights of the trial come from the completed Phase II where there is reasonable hypothesis that it will extend the median 44 months overall survival in these men to 57 months with some cases of full remission achieved. The trial will enroll 1200 men that will be randomized into two arms:
Schema:
De Novo Dx |SST until progression | OS
Stage T4x |Start ADT2| 6 months |If hormone sensitive Randomize |Definitive treatment 50% |OS
Surgery 67%, Radiation 33%
Other trials are looking at immune pathways in various settings. SWOG is working with the other co-ops to determine the best options for 2018.
Update on S1216 - SST v. Lupron plus TAK-700 in HSPC. This trial is enrolling 1300 men, is just 40 shy of closing, and will likely close by end of July. Whether or not TAK-700 will improve outcomes is not determined for two more years. However this trial will be one of the most beneficial trials to close as the secondary end points are huge pieces of information for CTC's and genetic biomarkers. Already the trial has validated CTC's as a predictive tool in metastatic men. Stay tuned on this one.
{Updated}
One of the key biomarkers in this trial is found in the tissue banking. These samples are taken before treatment begins (More than 1100 blood and 700 blocks thus far). And there is plenty to examine during disease progression making this trial the largest on record to take de novo sampling to be compared later.